Back to results
US 2012/0252808 A1Published application
Quinoline amide m1 receptor positive allosteric modulators
AssigneeMerck Sharp & Dohme Corp.
InventorsScott D. Kuduk, Kelly-Ann S. Schlegel, Zhi-Qiang Yang
Life of this patent
Estimating the term…
Abstract
The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
Claims23
A compound of formula (I):
- wherein
- X1 is selected from the group consisting of
- (1) N, and
- (2) N→O;
- X2-X3 is selected from the group consisting of
- (1) —CH2—CH2—,
- (2) —O—CH2—,
- (3) —CH2—O—, or
- (4) —CH2—;
- X4, X5, X6 and X7 are each selected from the group consisting of
- (1) N,
- (2) N→O,
- (3) CH,
- (4) O
- provided that one of X4, X5, X6 and X7 may be absent, thereby forming a five-membered ring;
- R1 is selected from the group consisting of
- (1) hydrogen,
- (2) halogen,
- (3) —C1-6 alkyl,
- (4) —C2-6 alkynyl,
- (4) phenyl,
- (5) ═O,
- (6) ═CH2,
- (7) hydroxyl,
- wherein the R1 alkyl, alkynyl or phenyl group is optionally substituted with one or more
- (a) hydroxyl, or
- (b) halogen;
- R2A and R2B are independently selected from the group consisting of
- (1) hydrogen,
- (2) hydroxyl, and
- (3) halogen,
- or R2A and R2B together form ═O;
- R3 is optionally present at one or more of the ring carbon atoms, and is independently selected from the group consisting of
- (1) halogen,
- (2) —O—C1-6 alkyl,
- (3) —S—C1-6 alkyl, or
- (4) a heteroaryl group, which is an aromatic cyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O or S, at least one of which is O, N, N→O or S, wherein the heteroaryl is optionally substituted with C1-6 alkyl;
- R4 is optionally present at one or more of the ring atoms, and is selected from the group consisting of
- (1) hydroxyl,
- (2) halogen,
- (3) —C1-6 alkyl,
- (4) —O—C1-6 alkyl,
- (5) —S—C1-6 alkyl,
- (6) —C3-8 cycloalkyl,
- (7) —C6-10 aryl,
- (8) —CN,
- (9) a heteroaryl group, which is an aromatic cyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O or S, at least one of which is O, N, N→O or S,
- (10) —O-heterocyclyl,
- (11) —NRARB,
- wherein RA and RB are selected from the group consisting of
- (a) hydrogen, or
- (b) —C1-6 alkyl,
- or RA and RB are linked together with the nitrogen to which they are attached to form a 4-6 membered carbocyclic ring, wherein one or two of the ring carbon atoms is optionally replaced by a nitrogen, oxygen or sulfur, and the ring is optionally substituted with one or more
- (a) halogen,
- (b) hydroxyl,
- (c) C1-6 alkyl,
- (d) —O—C1-6 alkyl,
- (e) —C1-6 alkyl;
- wherein n is 0-1;
- and the alkyl, cycloalkyl, aryl or heteroaryl R4 group is optionally substituted with one or more
- (a) halogen,
- (b) hydroxy,
- (c) —O—C1-6 alkyl,
- (d) —C1-6 alkyl,
- (e) —S—C1-6 alkyl, or
- (f) a heteroaryl group, which is an aromatic cyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O or S, at least one of which is O, N, N→O or S,
- wherein the alkyl, aryl or heteroaryl moiety is optionally substituted with one or more
- (i) halogen,
- (ii) hydroxy,
- (iii) —O—C1-6 alkyl, or
- (iv) —C1-6 alkyl;
- or two R4 groups are linked together to form a three or four atom fused ring heteroaryl group, said ring atoms selected from C, O, N, N→O or S, at least one of which is O, N, N→O or S,
- or a pharmaceutically acceptable salt thereof.
70 more elements
Dependencies are inferred from the claim text.